James Healy - 07 Jan 2022 Form 4/A - Amendment Insider Report for Coherus BioSciences, Inc. (CHRS)

Reporting relationship: Director
Issuer ticker: CHRS
Reported as of: 07 Jan 2022
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 11 Feb 2022, 15:14:30 UTC
Original report date: 10 Jan 2022
Prior SEC filing: 06 Jan 2022
Next SEC filing: 13 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ McDavid Stilwell, as Attorney-in-Fact for James I. Healy, M.D., Ph.D.

Key filing fact

James Healy filed Form 4/A - Amendment for Coherus BioSciences, Inc. (CHRS) on 11 Feb 2022.

Key facts

This page summarizes James Healy's Form 4/A - Amendment filing for Coherus BioSciences, Inc. (CHRS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2022, 15:14.

Change

Previous filing in this sequence was filed on 06 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +27,000
Change %
Price: $0.000000
Shares after: 27,000
Date: 07 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,000
Exercise price: $14.67
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.

Footnote F2

The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.